Document is current
Any future updates will be listed below
-
Authors
ter Avest, Mendy https://orcid.org/0000-0001-5757-4919
Langemeijer, Saskia M. C.
van den Heuvel, Lambertus P. W. J.
Baas, Laura M.
van de Kar, Nicole C. A. J.
ter Heine, Rob
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04079257 at ClinicalTrials.govDocuments that mention this clinical trial
Model-Informed Precision Dosing of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria
https://doi.org/10.1007/s40262-025-01536-x
- License Information
-
More Information
Article History
Accepted: 22 May 2025
First Online: 25 June 2025
Declarations
:
: No funding was received for the preparation of this article.
: Nicole C.A.J. van de Kar and BvdH are members of the European Reference Network for Rare Kidney Diseases (ERKNet)-Project No 739532. Nicole C.A.J. van de Kar received consultancy fees from Roche Pharmaceuticals, Alexion, and Novartis and is a sub-investigator in the APL2-C3G trial, Apellis. Rob ter Heine has received research funding from Amgen. Mendy ter Avest, Saskia M.C. Langemeijer, Lambertus P.W.J van den Heuvel, and Laura M. Baas have no conflicts of interest that are directly relevant to the content of this article.
: Ethics approval number: NL69637.091.19, 22 July, 2019.
: Not applicable.
: Not applicable.
: The participants of this study did not give written consent for their data to be shared publicly
: See Electronic Supplementary Material.
: MtA, SL, and RtH designed the research. MtA performed the research. LB analyzed the samples. MtA wrote the paper. Each author contributed important intellectual content during manuscript drafting or revision and all authors approved the final version.
